Podium to Practice: EHA 2026 – Multiple Myeloma: MAJESTEC-9

Podium to Practice: EHA 2026 – Multiple Myeloma: MAJESTEC-9

Podium to Practice: EHA 2026

Studies / Trials Discussed

S195 – MAJESTEC-9: A PHASE 3 STUDY OF TECLISTAMAB MONOTHERAPY VS POMALIDOMIDE/BORTEZOMIB/DEXAMETHASONE OR CARFILZOMIB/DEXAMETHASONE (PVD/KD) IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)

Icon Chair Speaker

Chair

Dr. Donna Reece

Icon Chair Speaker

Speakers

Dr. Darrell White

Dr. Maria Victoria Mateos Manteca

Explore more from your favourite experts – click their name to access their entire library of content.

Studies/trials discussed:

S195 – MAJESTEC-9: A PHASE 3 STUDY OF TECLISTAMAB MONOTHERAPY VS POMALIDOMIDE/BORTEZOMIB/DEXAMETHASONE OR CARFILZOMIB/DEXAMETHASONE (PVD/KD) IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM)

Abstract of the paper or summary description of the presentation:

LB5008 – TECLISTAMAB IMPROVES DEPTH OF RESPONSE AND PFS VERSUS LENALIDOMIDE-DEXAMETHASONE IN HIGH-RISK SMOLDERING MULTIPLE MYELOMA: RESULTS FROM THE PHASE 2 IMMUNOPRISM TRIAL

Tagged